Thursday, February 23, 2012

FDA targets October decision date for Impax Parkinson's drug

Impax Laboratories Inc.’s Parkinson’s disease treatment could be approved by late October, as the Food and Drug Administration accepted the Hayward company’s new drug application.
Impax (NASDAQ: IPXL), which last month said it will hire an undisclosed number of people as it prepares to sell the drug, said Thursday that its IPX-066 was given an FDA decision date of Oct. 21. The drug would be the first product from Impax's branded products unit, Impax Pharmaceuticals.

No comments:

Post a Comment